Openly is registered as a Class II medical device and provides medical-grade remote monitoring powered by a smartphone. Openly is part of Emyria’s Real-World Data capture platform and was built in close collaboration with our partners Happitech and WeGuide.
Currently, Openly is being used within the Early Digital Intervention for COVID Therapy (EDICT) research program to investigate the use of remote monitoring technologies in several key at-risk areas related to COVID-19, such as chronic respiratory patients and Aged Care residents.
This program is a collaboration between the University of Western Australia, Emyria, Sir Charles Gairdner Hospital and other industry partners.In the future, Openly may contribute to additional monitoring safety and efficacy outcomes data for participants of Emyria’s trials.
The global pandemic and the increasing demands on health care systems saw an urgent need to screen, monitor and manage patient health remotely. An increase in demand for alternative medical solutions was required to protect the vulnerable and reach those unable to access typical medical services.
There is also an ongoing need to collect accurate Real-World Data (RWD) to aid the drug registration. The number of Food and Drug Administration approvals where RWD played a significant role in the approval process now sits at 78 percent – and that number continues to rise.
Develop a unique, medical-grade, smartphone-based remote management tool to screen and monitor patients remotely with self reported surveys and vital sign measurements.
The medical-grade app uses a smartphone camera to remotely monitor heart rate (HR), heart rate variability (HRV) and atrial fibrillation (AF).
In May 2021, Openly achieved registration of the class IIa ‘Software as a Medical Device’ from Australia’s Therapeutic Goods Administration (TGA). Openly is now recognised as being able to capture medical-grade measurements of an individual’s heart rate, heart rate variability and atrial fibrillation status, remotely.
In February 2022 Openly won a major IT award, The ACS Digital Disrupter Award, “The Service Transformation for the Digital Consumer Award”, which recognises a project that uses innovative ways to change how an organisation provides their services to the consumer. READ MORE HERE
Currently, Openly is being used within the EDICT research which in collaboration with our academic and industry partners is investigating the use of remote monitoring technologies in several key at-risk areas related to COVID-19.
Openly’s application in other sectors of healthcare are being investigated to increase remote monitoring resources and alleviate the ever increasing pressure on health care systems.
- Class IIa registration means Emyria’s Real-World Evidence platforms are now capable of capturing medical-grade vital signs using just an Apple or Android smartphone.
- Obtaining this classification highlights Emyria’s commitment to formal regulatory approval of novel drug treatments and technologies for unmet clinical needs.
- Emyria, along with our academic and industry collaborators are investigating the benefits of Openly to remote monitor vulnerable patients including the elderly and patients with chronic respiratory conditions
- Emyria believes the unique features of Openly have applications in a variety of medical and consumer health monitoring settings where medical-grade remote monitoring can improve the care of patients with complex needs.